Inflammation, Not Cholesterol, Drives Heart Attacks in 'Healthy' Women — Statins May Help From Age 40

Solution-oriented medical advocacy framing that positions a single drug class as the definitive answer to a newly identified risk factor, using dramatic statistics to build urgency.

Pharmaceutical companies producing statins (largely Western-based) may see expanded market influence globally. Health systems in developing nations may face pressure to adopt broader statin screening protocols, increasing dependency on Western pharma supply chains. The US (Mass General Brigham) reinforces its dominance in setting global medical research agendas.

Similar to the 1980s-90s global adoption of statin therapy following US/EU clinical trials, which shaped international pharmaceutical trade and healthcare policy for decades.

Consumers may face increased healthcare spending on hsCRP screening tests and statin prescriptions starting at age 40, though generic statins cost as little as 2p per tablet, limiting financial burden. Broader preventive care uptake could reduce long-term hospitalization costs for cardiovascular events, potentially lowering insurance premiums over time.

Health regulators and national health systems may revise cardiovascular screening guidelines to include hsCRP testing, particularly for women aged 40+. Governments could expand statin prescription eligibility beyond traditional risk-factor criteria, increasing public health expenditure short-term but potentially reducing costly acute cardiac event treatments. NICE and equivalent bodies may face pressure to update clinical pathways.